Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2011 2
2015 1
2016 1
2017 3
2018 1
2019 2
2020 4
2021 2
2022 2
2023 3
2024 4
2025 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for F. araz m
Your search for F. Arazm retrieved no results
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Marso SP, et al. N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13. N Engl J Med. 2016. PMID: 27295427 Free PMC article. Clinical Trial.
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornøe CW, Ryan DH; SELECT Trial Investigators. Lincoff AM, et al. N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11. N Engl J Med. 2023. PMID: 37952131 Clinical Trial.
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, Jeppesen OK, Lingvay I, Mosenzon O, Pedersen SD, Tack CJ, Thomsen M, Vilsbøll T, Warren ML, Bain SC; PIONEER 6 Investigators. Husain M, et al. N Engl J Med. 2019 Aug 29;381(9):841-851. doi: 10.1056/NEJMoa1901118. Epub 2019 Jun 11. N Engl J Med. 2019. PMID: 31185157 Clinical Trial.
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, Charbonnel B, Frederich R, Gallo S, Cosentino F, Shih WJ, Gantz I, Terra SG, Cherney DZI, McGuire DK; VERTIS CV Investigators. Cannon CP, et al. N Engl J Med. 2020 Oct 8;383(15):1425-1435. doi: 10.1056/NEJMoa2004967. Epub 2020 Sep 23. N Engl J Med. 2020. PMID: 32966714 Clinical Trial.
Liraglutide and Renal Outcomes in Type 2 Diabetes.
Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators. Mann JFE, et al. N Engl J Med. 2017 Aug 31;377(9):839-848. doi: 10.1056/NEJMoa1616011. N Engl J Med. 2017. PMID: 28854085 Free article. Clinical Trial.
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR; TECOS Study Group. Green JB, et al. N Engl J Med. 2015 Jul 16;373(3):232-42. doi: 10.1056/NEJMoa1501352. Epub 2015 Jun 8. N Engl J Med. 2015. PMID: 26052984 Free article. Clinical Trial.
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.
Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, Flather M, Glynn RJ, Gregoire J, Jukema JW, Karpov Y, Kastelein JJP, Koenig W, Lorenzatti A, Manga P, Masiukiewicz U, Miller M, Mosterd A, Murin J, Nicolau JC, Nissen S, Ponikowski P, Santos RD, Schwartz PF, Soran H, White H, Wright RS, Vrablik M, Yunis C, Shear CL, Tardif JC; SPIRE Cardiovascular Outcome Investigators. Ridker PM, et al. N Engl J Med. 2017 Apr 20;376(16):1527-1539. doi: 10.1056/NEJMoa1701488. Epub 2017 Mar 17. N Engl J Med. 2017. PMID: 28304242 Free article. Clinical Trial.
The Role of (18)F-FDOPA PET/CT in Recurrent Medullary Thyroid Cancer Patients with Elevated Serum Calcitonin Levels.
Araz M, Soydal Ç, Demir Ö, Gökcan MK, Küçük NÖ. Araz M, et al. Mol Imaging Radionucl Ther. 2023 Feb 23;32(1):1-7. doi: 10.4274/mirt.galenos.2022.81904. Mol Imaging Radionucl Ther. 2023. PMID: 36815513 Free PMC article.
The sensitivity and diagnostic performance of (18)F-DOPA PET/CT were investigated. RESULTS: A total of 14 patients (9 F and 5 M; median age: 45) were included in the analysis. ...Median maximum standardized uptake value for the recurrent or metastatic lesions were c …
The sensitivity and diagnostic performance of (18)F-DOPA PET/CT were investigated. RESULTS: A total of 14 patients (9 F and 5 …
Prognostic Importance of (18)F-FDG Positron Emission Tomography in Uterine Cervical Cancer.
Soydal Ç, Baltacıoğlu MH, Araz M, Demir B, Dursun E, Taşkın S, Küçük NÖ, Ortaç F. Soydal Ç, et al. Among authors: araz m. Mol Imaging Radionucl Ther. 2024 Oct 7;33(3):167-173. doi: 10.4274/mirt.galenos.2024.57984. Mol Imaging Radionucl Ther. 2024. PMID: 39373155 Free PMC article.
OBJECTIVES: The aim of this study was to evaluate the prognostic value of (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography/computed tomography (PET/CT) in the uterine cervix cancer patients. METHODS: Thirty-two women (mean age: 52.712.6) who underwe …
OBJECTIVES: The aim of this study was to evaluate the prognostic value of (18)F-fluorodeoxyglucose ((18)F-FDG) positron emissi …
Transarterial Radioembolization in the TACOME Trial: Dosimetric Analysis and Clinical Features in Predicting Response and Overall Survival.
Soydal C, Araz M, Demir B, Ones T, Sonmezoglu K, Selcuk NA, Balli T, Isık EG, Salancı BV, Derebek E, Kesim S, Sahin OE, Piskin FC, Celebioglu EC, Bilgic MS, Kucuk NO. Soydal C, et al. Among authors: araz m. J Nucl Med. 2025 Jul 1;66(7):1097-1104. doi: 10.2967/jnumed.125.269519. J Nucl Med. 2025. PMID: 40404391
Treatment to response was evaluated by [(18)F]-FDG PET images. Results: In total, 176 patients (112 men and 64 women) were included in the analysis. ...
Treatment to response was evaluated by [(18)F]-FDG PET images. Results: In total, 176 patients (112 men and 64 women) were included i …
31 results